Neurocrine Biosciences Inc. (NBIX)

Live Audio Webcast will be on June 6, 2019

- Nearly 30% of Patients with Possible Tardive Dyskinesia Reported Moderate-to-Extreme Problems Performing Their Usual Activities, Including Work, Housework and Leisure Activities

- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life

Live Audio Webcast will be on May 14, 2019

- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients

- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease

- More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer

- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders

INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx

Conference Call and Webcast Scheduled for Monday, April 29

- NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept

SAN DIEGO, March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor...

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx

INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis

Conference Call and Webcast Scheduled for Tuesday, February 5

- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $130 Million with Approximately 22,900 TRx

Live Audio Webcast will be on January 7, 2019

Here are the top healthcare bets ticking all the boxes for analysts.

Stay active and selective: These are the five best stocks to invest in right now

Not every trade can be a winner, so let's lighten the load here.

Analysts weren't shy to defend the company after Tuesday's earnings.

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

A roundup of biotech names with actions pending at the FDA in coming weeks.

Technology and biotech companies seem to be among the big winners.

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.